$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

$sxtp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023088610 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$42.71K	$51.19K	$558.5K
YoY Change	-91.65%	-90.84%
Cost Of Revenue	$146.3K	$71.20K	$308.0K
YoY Change	-66.17%	-76.89%
Gross Profit	-$103.6K	-$20.01K	$250.5K
YoY Change	-231.34%	-107.99%
Gross Profit Margin	-242.45%	-39.09%	44.85%
Selling, General & Admin	$1.690M	$1.314M	$839.2K
YoY Change	29.66%	56.54%
% of Gross Profit			334.97%
Research & Development	$100.2K	$263.7K	$477.1K
YoY Change	-80.93%	-44.73%
% of Gross Profit			190.45%
Depreciation & Amortization	$10.42K	$5.485K	$23.53K
YoY Change	12.77%	-76.69%
% of Gross Profit			9.39%
Operating Expenses	$1.791M	$1.577M	$1.316M
YoY Change	-2.11%	19.83%
Operating Profit	-$1.894M	-$1.522M	-$1.066M
YoY Change	8.21%	42.79%
Interest Expense	-$138.1K	$40.11K	-$3.163M
YoY Change	-96.94%	-101.27%
% of Operating Profit
Other Income/Expense, Net	-$13.95K	-$70.49K	-$29.81K
YoY Change	-67.74%	136.46%
Pretax Income	-$2.046M	$4.174M	-$4.259M
YoY Change	-66.88%	-198.0%
Income Tax	$60.00	$63.00	$750.00
% Of Pretax Income		0.0%
Net Earnings	-$2.131M	$4.183M	-$4.258M
YoY Change	-65.52%	-198.24%
Net Earnings / Revenue	-4990.54%	8172.22%	-762.39%
Basic Earnings Per Share		$0.77	-$0.61
Diluted Earnings Per Share	-$0.37	$0.77	-$0.76
COMMON SHARES
Basic Shares Outstanding	5.800M shares	5.800M shares	2.386M shares
Diluted Shares Outstanding		5.319M shares	2.386M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.142M	$2.219M	$439.4K
YoY Change	708.88%	404.91%
Cash & Equivalents	$2.142M	$2.219M	$439.4K
Short-Term Investments
Other Short-Term Assets	$4.403M	$5.940M	$161.8K
YoY Change	1533.01%	3572.06%
Inventory	$466.2K	$598.3K	$725.5K
Prepaid Expenses
Receivables	$231.3K	$138.0K	$195.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.243M	$8.895M	$1.522M
YoY Change	559.02%	484.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$71.28K	$3.836K	$53.02K
YoY Change	109.96%	-92.76%
Goodwill
YoY Change
Intangibles	$227.3K	$225.0K
YoY Change	38.36%
Long-Term Investments
YoY Change
Other Assets	$242.7K		$6.030K
YoY Change
Total Long-Term Assets	$541.2K	$255.4K	$167.0K
YoY Change	173.03%	52.95%
TOTAL ASSETS
Total Short-Term Assets	$7.243M	$8.895M	$1.522M
Total Long-Term Assets	$541.2K	$255.4K	$167.0K
Total Assets	$7.784M	$9.150M	$1.689M
YoY Change	500.04%	441.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$506.2K	$271.6K	$454.1K
YoY Change	-33.28%	-40.19%
Accrued Expenses	$13.65K	$26.80K	$33.83K
YoY Change	5.0%	-20.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.770K	$8.770K
YoY Change	-99.96%
Total Short-Term Liabilities	$2.835M	$2.481M	$2.085M
YoY Change	-88.15%	18.99%
LONG-TERM LIABILITIES
Long-Term Debt	$150.3K		$21.50M
YoY Change	-88.17%
Other Long-Term Liabilities	$0.00	$0.00	$353.9K
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$150.3K	$152.6K	$21.85M
YoY Change	-90.15%	-99.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.835M	$2.481M	$2.085M
Total Long-Term Liabilities	$150.3K	$152.6K	$21.85M
Total Liabilities	$2.914M	$2.634M	$23.36M
YoY Change	-88.29%	-88.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.58M	-$30.57M
YoY Change	13.07%
Common Stock	$581.00	$580.00
YoY Change	143.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.870M	$6.554M	-$21.67M
YoY Change
Total Liabilities & Shareholders Equity	$7.784M	$9.150M	$1.689M
YoY Change	500.04%	441.87%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.131M	$4.183M	-$4.258M
YoY Change	-65.52%	-198.24%
Depreciation, Depletion And Amortization	$10.42K	$5.485K	$23.53K
YoY Change	12.77%	-76.69%
Cash From Operating Activities	-$63.67K	-$3.753M	-$944.0K
YoY Change	-3.5%	297.57%
INVESTING ACTIVITIES
Capital Expenditures	$66.56K	$27.91K	$1.490K
YoY Change	13.51%	1773.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$66.56K	-$27.91K	-$1.490K
YoY Change	13.51%	1773.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	5.971M	1.290M
YoY Change	-100.0%	362.75%
NET CHANGE
Cash From Operating Activities	-63.67K	-3.753M	-944.0K
Cash From Investing Activities	-66.56K	-27.91K	-1.490K
Cash From Financing Activities	0.000	5.971M	1.290M
Net Change In Cash	-130.2K	2.190M	344.9K
YoY Change	-32.61%	535.1%
FREE CASH FLOW
Cash From Operating Activities	-$63.67K	-$3.753M	-$944.0K
Capital Expenditures	$66.56K	$27.91K	$1.490K
Free Cash Flow	-$130.2K	-$3.781M	-$945.5K
YoY Change	4.5%	299.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41719
	dei	Entity Registrant Name EntityRegistrantName	60 DEGREES PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2406880
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1025 Connecticut Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW Suite 1000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20036
	dei	City Area Code CityAreaCode	(202)
	dei	Local Phone Number LocalPhoneNumber	327-5422
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5799535	shares
CY2023Q3	us-gaap	Cash Cash	2218540	usd
CY2022Q4	us-gaap	Cash Cash	264865	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	138009	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45965	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	5939927	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	200967	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	68629	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	598319	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8894795	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1099004	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3836	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26534	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12647	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	225047	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	164255	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	251581	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	176902	usd
CY2023Q3	us-gaap	Assets Assets	9150212	usd
CY2022Q4	us-gaap	Assets Assets	1297206	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	271602	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	758668	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26800	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	325000	usd
CY2022Q4	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest	195097	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	4276609	usd
CY2023Q3	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	2750	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	16855887	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2174194	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1129840	usd
CY2022Q4	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties	364360	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2481368	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23921211	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	255000	usd
CY2023Q3	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	152594	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2022Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	1109783	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	152594	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1525055	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2633962	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25446266	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	78803	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	78803	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	9858040	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	580	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	239	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27182915	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5164461	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	81386	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	73708	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30568566	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28815148	usd
CY2023Q3	sxtp	Shareholders Equity Deficit ShareholdersEquityDeficit	6554355	usd
CY2022Q4	sxtp	Shareholders Equity Deficit ShareholdersEquityDeficit	-23576740	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-38105	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-572320	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6516250	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9150212	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1297206	usd
CY2023Q3	us-gaap	Revenues Revenues	51188	usd
CY2022Q3	us-gaap	Revenues Revenues	168185	usd
	us-gaap	Revenues Revenues	127892	usd
	us-gaap	Revenues Revenues	260382	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	71196	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	92281	usd
	us-gaap	Cost Of Revenue CostOfRevenue	328293	usd
	us-gaap	Cost Of Revenue CostOfRevenue	269535	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-20008	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	75904	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-200401	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-9153	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	75566	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	150262	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	82974	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	259669	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	55558	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	226166	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-117427	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	250516	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	263703	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27655	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	591569	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	322106	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1313617	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	413627	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2551426	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	994157	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1577320	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	441282	usd
	us-gaap	Operating Expenses OperatingExpenses	3142995	usd
	us-gaap	Operating Expenses OperatingExpenses	1316263	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1521762	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-215116	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3260422	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1065747	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	40106	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1215978	usd
	us-gaap	Interest Expense InterestExpense	2281191	usd
	us-gaap	Interest Expense InterestExpense	2883714	usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399725	usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-504613	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	92490	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-22495	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	95324	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-23496	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-391593	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	6105066	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5379269	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70490	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3172	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-69169	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29810	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5695367	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1235301	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1493028	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3441633	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4173605	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1450417	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1767394	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4507380	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	750	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1450667	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
	us-gaap	Profit Loss ProfitLoss	-4508130	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9656	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3172	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14165	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1454	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4183198	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1447495	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1753418	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4506676	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1450667	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
	us-gaap	Profit Loss ProfitLoss	-4508130	usd
CY2023Q3	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	9342	usd
CY2022Q3	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	-6417	usd
	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	7678	usd
	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	-20850	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4182884	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1457084	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1759905	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4528980	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-9656	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-3172	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-14165	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-1454	usd
CY2022Q3	sxtp	Unrealized Foreign Currency Translation Loss From Noncontrolling Interest UnrealizedForeignCurrencyTranslationLossFromNoncontrollingInterest	-544	usd
	sxtp	Unrealized Foreign Currency Translation Loss From Noncontrolling Interest UnrealizedForeignCurrencyTranslationLossFromNoncontrollingInterest	-544	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4192540	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1453368	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1745740	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4526982	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	101538	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	101538	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4091002	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1453368	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1847278	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4526982	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5319255	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2386009	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3344843	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2361569	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18154484	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	96556	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-907447	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18965375	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	185335	usd
CY2022Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-110989	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2150016	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-21041045	usd
CY2022Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-6417	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1450667	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22498129	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5378908	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-1290	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2597534	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-21368976	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-374	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3343591	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24712941	usd
CY2023Q3	sxtp	Issuance Of Common Stock For Payment Of Deferred Compensation IssuanceOfCommonStockForPaymentOfDeferredCompensation	155000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7989598	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	10128500	usd
CY2023Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	838748	usd
CY2023Q3	sxtp	Net Of Underwriting Discounts And Offering Costs NetOfUnderwritingDiscountsAndOfferingCosts	1266740	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6235276	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1131771	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	187200	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	271066	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	109148	usd
CY2023Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	9342	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6516250	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
	us-gaap	Profit Loss ProfitLoss	-4508130	usd
	us-gaap	Depreciation Depreciation	19287	usd
	us-gaap	Depreciation Depreciation	20747	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20606	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2783	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	669148	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	821154	usd
	sxtp	Amortization Of Rou Asset AmortizationOfROUAsset	-37035	usd
	sxtp	Amortization Of Rou Asset AmortizationOfROUAsset	-33848	usd
	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts	-67728	usd
	sxtp	Amortization Of Capitalized Services AmortizationOfCapitalizedServices	-690173	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	670871	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-95324	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	23496	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	399725	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	504613	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5379269	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-139946	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	92044	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48679	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1512578	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-58083	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-60205	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	36415	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-489337	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-36199	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1267703	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-2055810	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37122	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-34271	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-100000	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	199157	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4479242	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-944003	usd
	us-gaap	Payments For Software PaymentsForSoftware	29220	usd
	us-gaap	Payments For Software PaymentsForSoftware	1488	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1823	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18283	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49326	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1488	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	150420	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6454325	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1131771	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	185335	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	305000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1611111	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	250000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6474565	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1290335	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7678	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	20850	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1953675	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	323994	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115399	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2218540	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	439393	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	7989598	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10128500	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	270460	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4916556	usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal	50922	usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal	50570	usd
	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock	4979365	usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	650000	usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	1105000	usd
	us-gaap	Stock Issued1 StockIssued1	480000	usd
	sxtp	Stock Issued For Acquisition Of Intangibles StockIssuedForAcquisitionOfIntangibles	33895	usd
	us-gaap	Notes Issued1 NotesIssued1	301416	usd
	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified	838748	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiaries (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Initial Public Offering</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses payable by the Company (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, which is equal to 110% of the offering price per Unit (the “Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. See Note 6 for further details.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as a business combination or other profitable investment may be achieved.</p>
CY2023Q3	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	1	pure
CY2023Q3	sxtp	Common Shares Isuued CommonSharesIsuued	904436	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Use of Estimates</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset.</p>
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	108208	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	183943	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	149812	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Concentrations</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up 10% of receivables or revenues. 100% of receivables as of September 30, 2023, consisting of two significant customers at 78% and 22%, are outstanding from significant customers. At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were outstanding from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers (100% for the three months ended September 30, 2022 consisting of three significant customers at 48%, 43%, and 9%). For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28% (100% for the nine months ended September 30, 2022, consisting of three customers at 65%, 29%, and 6% respectively).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company. The terms of the preferred share conversion with Knight Therapeutics currently limits the Company’s ability to access additional credit without their consent.</p>
	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	Significant customers represent any customer whose business makes up 10% of receivables or revenues. 100% of receivables as of September 30, 2023, consisting of two significant customers at 78% and 22%, are outstanding from significant customers. At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were outstanding from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers (100% for the three months ended September 30, 2022 consisting of three significant customers at 48%, 43%, and 9%). For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28% (100% for the nine months ended September 30, 2022, consisting of three customers at 65%, 29%, and 6% respectively).
	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0	pure
CY2022	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.85	pure
CY2023Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	263703	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	591569	usd
CY2022Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	182655	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	477106	usd
CY2023Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	525000	shares
	sxtp	Common Stock Shares As Sharebased Payments CommonStockSharesAsSharebasedPayments	405000	shares
	sxtp	Unamortized Deferred Prepaid Research And Development Costs UnamortizedDeferredPrepaidResearchAndDevelopmentCosts	2834148	usd
CY2022	sxtp	Unamortized Deferred Prepaid Research And Development Costs UnamortizedDeferredPrepaidResearchAndDevelopmentCosts	0	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	2174194	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1494200	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	63062	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Reclassifications</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive income (loss), shareholders’ and members’ equity (deficit), or cash flows.</p>
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	513000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1063235	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	350362	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	397487	usd
CY2023Q3	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	73391	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	97486	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	681773	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	741978	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	83454	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	223400	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	598319	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	150025	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	148202	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	146189	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	126902	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3836	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
	us-gaap	Depreciation Depreciation	19287	usd
	us-gaap	Depreciation Depreciation	20747	usd
CY2023Q3	us-gaap	Depreciation Depreciation	5485	usd
CY2022Q3	us-gaap	Depreciation Depreciation	6901	usd
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	174833	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	145613	usd
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	79248	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	27070	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	254081	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	172683	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-29034	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-8428	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	225047	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	164255	usd
CY2023Q3	us-gaap	Development Costs DevelopmentCosts	12283	usd
CY2022Q3	us-gaap	Development Costs DevelopmentCosts	0	usd
	us-gaap	Development Costs DevelopmentCosts	52178	usd
	us-gaap	Development Costs DevelopmentCosts	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20606	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2783	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7414	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1831	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	83808	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	78803	shares
CY2022Q4	sxtp	Percentage Of Cancelled Shares Issued PercentageOfCancelledSharesIssued	0.61	pure
CY2022Q4	sxtp	Percentage Of Cancelled Shares Outstanding PercentageOfCancelledSharesOutstanding	0.61	pure
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31447	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31447	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29245	shares
CY2023Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	214934	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	60000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93000	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	45560	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231917	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231917	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	151991	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	151991	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q2	sxtp	Percentage Of Ipo Price PercentageOfIPOPrice	1.10	pure
CY2023Q2	sxtp	Percentage Of Ipo Price PercentageOfIPOPrice	1.10	pure
CY2023Q3	sxtp	Share Based Compensation Arrangement By Share Based Payment Number Of Warrants Reclassified From Derivative Liabilities ShareBasedCompensationArrangementByShareBasedPaymentNumberOfWarrantsReclassifiedFromDerivativeLiabilities	231917	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	5.46
CY2023Q3	sxtp	Weighted Average Remaining Contractual Life Years Reclassified From Derivative Liabilitiesin WeightedAverageRemainingContractualLifeYearsReclassifiedFromDerivativeLiabilitiesin	P4Y1M24D
CY2023Q3	sxtp	Class Of Number Of Warrants Granted ClassOfNumberOfWarrantsGranted	3116384	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.22
CY2023Q3	sxtp	Weighted Average Remaining Contractual Life Years Granted WeightedAverageRemainingContractualLifeYearsGranted	P5Y
CY2023Q3	sxtp	Class Of Number Of Warrants Exercised ClassOfNumberOfWarrantsExercised	-184447	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.14
CY2023Q3	sxtp	Weighted Average Remaining Contractual Life Years Exercised WeightedAverageRemainingContractualLifeYearsExercised	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3163854	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.17
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M23D
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3163854	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.17
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y8M23D
CY2023Q3	us-gaap	Transfer Of Financial Assets Accounted For As Sales Cash Proceeds Received For Assets Derecognized Amount TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount	1131771	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31447	shares
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.06	pure
CY2020Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	100000	usd
CY2022Q2	sxtp	Deferred Cash DeferredCash	60000	usd
CY2022Q2	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	400000	usd
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	100000	usd
CY2023Q3	sxtp	Equity Compensation EquityCompensation	245000	usd
CY2023Q3	us-gaap	Shares Issued SharesIssued	29245	shares
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	57198	usd
CY2022Q2	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	12500	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1	pure
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	38900	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	60000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	5
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	325000	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	20596595	usd
CY2017Q4	sxtp	Promissory Note Amount PromissoryNoteAmount	750000	usd
CY2017Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.10	pure
CY2022Q1	us-gaap	Long Term Debt Maturities Repayment Terms LongTermDebtMaturitiesRepaymentTerms	30 days
CY2023Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	120683	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	1767	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3869	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	52628	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	4944	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	29429	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	66558	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	85242	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	214934	shares
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	223077	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	17965670	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16855887	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	1109783	usd
CY2023Q2	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	22222	usd
	sxtp	Description Of2022 And2023 Bridge Note DescriptionOf2022And2023BridgeNote	As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 303,982 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488 for the outstanding principal, accrued interest and Extension Payments (2022 Bridge Notes only), in full settlement of the outstanding debt obligations. The embedded derivative liability (conversion feature) was marked to market on the settlement date, and the Company recognized a debt extinguishment loss of $614,670 upon settlement, representing the difference between (i) the reacquisition price, consisting of cash and shares, and (ii) the net carrying value of the debt including associated derivative liabilities on the date of conversion.
CY2022Q2	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	8472	usd
	sxtp	Description Of Related Party Notes DescriptionOfRelatedPartyNotes	As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 79,926 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding accrued interest and Extension Payments. The Company recognized a final mark to market adjustment of the embedded derivative liability (conversion feature), and as a result, no gain or loss was recognized on the debt extinguishment.
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10770037	usd
	sxtp	Initial Public Offering Discount Percentages InitialPublicOfferingDiscountPercentages	0.15	pure
	sxtp	Common Stock Outstanding Percentages CommonStockOutstandingPercentages	0.199	pure
	sxtp	Payment Of Milestones PaymentOfMilestones	10000000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
CY2023Q1	sxtp	Cumulative Dividend Percentage CumulativeDividendPercentage	0.06	pure
CY2023Q3	sxtp	Common Stock Ownership Percentage CommonStockOwnershipPercentage	0.199	pure
CY2022Q1	sxtp	Equal Royalty Pay To Lender Percentage EqualRoyaltyPayToLenderPercentage	3.5	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	839887	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21520650	usd
CY2023Q1	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	339052	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	634243	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21815841	usd
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-1064849	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	659306	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23539996	usd
CY2023Q3	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	6105066	usd
CY2023Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	17434930	usd
	sxtp	Description Of Knight Debt Conversion Agreement DescriptionOfKnightDebtConversionAgreement	As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,106,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment.
CY2019Q2	us-gaap	Debt Current DebtCurrent	3000000	usd
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2100000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	279061	usd
CY2022Q4	us-gaap	Public Utilities Property Plant And Equipment Original Cost Of Intangible Utility Plants PublicUtilitiesPropertyPlantAndEquipmentOriginalCostOfIntangibleUtilityPlants	3000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	279061	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2720939	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	1555670	usd
CY2022Q4	sxtp	Debenture Debenture	4276609	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	sxtp	Annual Interest Rate AnnualInterestRate	0.0375	pure
CY2020Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	731	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	731	usd
	sxtp	Long Term Debt Current Maturitie LongTermDebtCurrentMaturitie	8772	usd
CY2023Q3	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	152594	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	2750	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2804	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	147196	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	150000	usd
	sxtp	Payment Terms Balloon Payment To Be Paid PaymentTermsBalloonPaymentToBePaid	32383	usd
CY2023Q2	sxtp	Short Term Advance Received ShortTermAdvanceReceived	50000	usd
CY2023Q2	sxtp	Short Term Advance Received ShortTermAdvanceReceived	250000	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1483888	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	979275	usd
CY2022Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	504613	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	954725	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	555000	usd
CY2023Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	399725	usd
CY2022Q4	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1494200	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	5134	usd
CY2023Q1	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1499334	usd
CY2023Q2	sxtp	Fair Value Commitment Date FairValueCommitmentDate	954725	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	-7968	usd
CY2023Q2	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	2446091	usd
CY2023Q3	sxtp	Fair Value Mark To Market Adjustment Prior To Conversion Or Reclassification FairValueMarkToMarketAdjustmentPriorToConversionOrReclassification	-149542	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1457801	usd
CY2023Q3	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified	-838748	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2117142	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	57052	usd
CY2023Q3	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	2174194	usd
	sxtp	Fair Value Commitment Date FairValueCommitmentDate	1483888	usd
	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	1001	usd
CY2022Q2	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1484889	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	22495	usd
CY2022Q3	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1507384	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-95324	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	23496
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	750	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	187196	usd
CY2023Q3	us-gaap	Deferred Compensation Arrangement With Individual Shares Authorized For Issuance DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance	40000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	sxtp	Aggregate Of Stock Option AggregateOfStockOption	607924	shares
CY2023Q3	sxtp	Share Baseed Compensation Of Stock Option Award ShareBaseedCompensationOfStockOptionAward	233728	usd
	sxtp	Share Baseed Compensation Of Stock Option Award ShareBaseedCompensationOfStockOptionAward	233728	usd
CY2022Q3	sxtp	Share Baseed Compensation Of Stock Option Award ShareBaseedCompensationOfStockOptionAward	0	usd
	sxtp	Share Baseed Compensation Of Stock Option Award ShareBaseedCompensationOfStockOptionAward	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	32000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	8000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet		usd
CY2023Q3	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.15	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13992	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13992	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27984	usd
	sxtp	Lessee Operating Lease Liability Payments Due Imputed Interest LesseeOperatingLeaseLiabilityPaymentsDueImputedInterest	1184	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	26800	usd
CY2023Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	26800	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15	pure
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	13859	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	12974	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	41225	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	38921	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	43581	usd
CY2023Q4	sxtp	Return The Deposited Funds ReturnTheDepositedFunds	820000	usd
CY2023Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent		usd
CY2023Q3	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest		usd
CY2023Q3	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2023Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2023Q3	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties		usd
CY2023Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent		usd
CY2023Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2023Q3	sxtp	Unrealized Foreign Currency Translation Loss From Noncontrolling Interest UnrealizedForeignCurrencyTranslationLossFromNoncontrollingInterest		usd
	sxtp	Unrealized Foreign Currency Translation Loss From Noncontrolling Interest UnrealizedForeignCurrencyTranslationLossFromNoncontrollingInterest		usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2361569	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2386009	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3344843	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5319255	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	sxtp	Cancellation Of Common Stock CancellationOfCommonStock		usd
CY2023Q3	sxtp	Voluntary Conversion Of Series A Preferred Stock Into Common Stock VoluntaryConversionOfSeriesAPreferredStockIntoCommonStock		usd
CY2023Q3	sxtp	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest		usd
	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts		usd
	sxtp	Amortization Of Capitalized Services AmortizationOfCapitalizedServices		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal		usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal		usd
	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	sxtp	Stock Issued For Acquisition Of Intangibles StockIssuedForAcquisitionOfIntangibles		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified		usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2023Q3	sxtp	Class Of Number Of Warrants Forfeited ClassOfNumberOfWarrantsForfeited		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q3	sxtp	Class Of Number Of Warrants Expired ClassOfNumberOfWarrantsExpired		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure		usd
CY2023Q3	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure		usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q3	us-gaap	Public Utilities Property Plant And Equipment Original Cost Of Intangible Utility Plants PublicUtilitiesPropertyPlantAndEquipmentOriginalCostOfIntangibleUtilityPlants		usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q3	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts		usd
CY2023Q3	sxtp	Debenture Debenture		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2023Q3	us-gaap	Long Term Debt Maturing In Years Two And Three LongTermDebtMaturingInYearsTwoAndThree		usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001946563

Files In Submission

Name	View Source	Status
0001213900-23-088610-index-headers.html	Edgar Link	pending
0001213900-23-088610-index.html	Edgar Link	pending
0001213900-23-088610.txt	Edgar Link	pending
0001213900-23-088610-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_60degrees.htm	Edgar Link	pending
f10q0923ex31-2_60degrees.htm	Edgar Link	pending
f10q0923ex32-1_60degrees.htm	Edgar Link	pending
f10q0923ex32-2_60degrees.htm	Edgar Link	pending
f10q0923_60degrees.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_60degrees_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sxtp-20230930.xsd	Edgar Link	pending
sxtp-20230930_cal.xml	Edgar Link	unprocessable
sxtp-20230930_def.xml	Edgar Link	unprocessable
sxtp-20230930_pre.xml	Edgar Link	unprocessable
sxtp-20230930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2023 Q4 Form 10-Q Financial Statement

#000121390023088610 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP 60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2023 Q4 Form 10-Q Financial Statement

#000121390023088610 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp